基于药物基因组学的急性缺血性卒中个体化抗栓治疗进展 Advances in Pharmacogenomics-Based Individualized Antithrombotic Therapy for Acute Ischemic Stroke
抗栓治疗是预防急性缺血性卒中复发的关键手段。随着多组学研究的进展和越来越多影响药物安全性和有效性的相关基因被发现，药物基因组学在个体化治疗中的应用逐渐受到关注。本文阐述了药物基因组学在急性缺血性卒中患者抗栓治疗中的指导作用的研究进展，旨在挖掘通过基因检测优化药物选择与剂量调整的潜力。研究表明，氯吡格雷等药物的疗效因细胞色素P450酶家族2亚家族C成员19（cytochrome P450 family 2 subfamily C member 19，CYP2C19）基因多态性而异，携带CYP2C19*2或CYP2C19*3等功能缺失等位基因的患者对标准抗血小板治疗反应较差，不能有效降低卒中复发风...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Chinese Journal of Stroke
2024-10-01
|
| Series: | Zhongguo cuzhong zazhi |
| Subjects: | |
| Online Access: | http://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2024.10.001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!